Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis

Journal of Rheumatology

Volumn 39, Issue 4, 2012, Pages 787-794

  Hudson, Marie ^a   Mahler, Michael ^b   Pope, Janet ^c   You, Daniel ^d   Tatibouet, Solene ^a   Steele, Russell ^a   Baron, Murray ^a   Fritzler, Marvin ^d   Markland, J ^e   Robinson, D ^e   Jones, N ^e   Khalidi, N ^e   Docherty, P ^e   Kaminska, E ^e   Masetto, A ^e   Sutton, E ^e   Mathieu, J P ^e   Ligier, S ^e   Grodzicky, T ^e   Thorne, C ^e   LeClercq, S ^e   more..

^a MCGILL UNIVERSITY   (Canada)

^b INOVA DIAGNOSTICS INC   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e NONE

Author keywords

Anticentromere antibodies; Autoantibodies; CENP A antibodies; CENP B antibodies; Systemic sclerosis

Indexed keywords

CENTROMERE ANTIBODY; CENTROMERE PROTEIN A; CENTROMERE PROTEIN B;

ADULT; ANTIBODY DETECTION; ARTHRITIS; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOFLUORESCENCE; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MYOSITIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLERODERMA; SEROLOGY; SKIN ABSORPTION; SKIN ULCER; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOANTIGENS; CENTROMERE PROTEIN B; CHROMOSOMAL PROTEINS, NON-HISTONE; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SCLERODERMA, SYSTEMIC; SKIN DISEASES;

EID: 84859454401     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/rheum.111133     Document Type: Article

References (30)

1. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42. (Pubitemid 41111469)
2. Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: Anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003;49:399-412. (Pubitemid 36682409)
3. Dick T, Mierau R, Bartz-Bazzanella P, Alavi M, Stoyanova-Scholz M, Kindler J, et al. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 2002;61:121-7. (Pubitemid 34098426)
4. Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007;19:580-91. (Pubitemid 47530879)
5. Robitaille G, Christin MS, Clement I, Senecal JL, Raymond Y. Nuclear autoantigen CENP-B transactivation of the epidermal growth factor receptor via chemokine receptor 3 in vascular smooth muscle cells. Arthritis Rheum 2009;60:2805-16.
6. Henault J, Robitaille G, Senecal JL, Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006;54:963-73.
7. Henault J, Tremblay M, Clement I, Raymond Y, Senecal JL. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 2004;50:3265-74. (Pubitemid 39372004)
8. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58:3902-12.
9. Denton CP, Lapadula G, Mouthon L, Muller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology 2009;48 Suppl 3:iii32-5.
10. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research Group database. Ann Rheum Dis 2007;66:754-63.
11. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003;5:80-93. (Pubitemid 36849754)
12. Fritzler MJ, Rattner JB, Luft LM, Edworthy SM, Casiano CA, Peebles C, et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 2011;10:194-200.
13. Mahler M, Fritzler MJ. Epitope specificity and significance in systemic autoimmune diseases. Ann NY Acad Sci 2010;1183: 267-87.
14. Mahler M, Maes L, Blockmans D, Westhovens R, Bossuyt X, Riemekasten G, et al. Clinical and serological evaluation of a novel CENP-A peptide based ELISA. Arthritis Res Ther 2010;12:R99.
15. Hanke K, Becker MO, Brueckner CS, Meyer W, Janssen A, Schlumberger W, et al. Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis. J Rheumatol 2010;37:2548-52.
16. Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol 2007;34:1528-34. (Pubitemid 47067990)
17. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5. (Pubitemid 18073738)
19. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: Development and testing. J Rheumatol 1999;26:2159-67. (Pubitemid 29487010)
20. Ashida R, Ihn H, Mimura Y, Jinnin M, Asano Y, Kubo M, et al. Clinical features of scleroderma patients with contracture of phalanges. Clin Rheumatol 2007;26:1275-7. (Pubitemid 47034182)
21. Baron M, Lee P, Keystone EC. The articular manifestations of progressive systemic sclerosis (scleroderma). Ann Rheum Dis 1982;41:147-52. (Pubitemid 12158516)
22. Randone SB, Guiducci S, Cerinic MM. Musculoskeletal involvement in systemic sclerosis. Best Pract Res Clin Rheumatol 2008;22:339-50. (Pubitemid 351606948)
23. Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: Comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008;35:458-65. (Pubitemid 351374421)
24. Craft JE, Hardin JA. Linked sets of antinuclear antibodies: what do they mean? J Rheumatol Suppl. 1987 Jun;14:106-9.
25. Theofilopoulos AN. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol Today 1995;16:90-8.
26. Mahler M, Mierau R, Genth E, Bluthner M. Development of a CENP-A/CENP-B-specific immune response in a patient with systemic sclerosis. Arthritis Rheum 2002;46:1866-72. (Pubitemid 34774519)
27. Mahler M, Mierau R, Bluthner M. Fine-specificity of the anti-CENP-A B-cell autoimmune response. J Mol Med 2000;78:460-7.
28. Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 1996;184:765-70. (Pubitemid 26324132)
29. Johnson SR, Feldman BM, Hawker GA. Classification criteria for systemic sclerosis subsets. J Rheumatol 2007;34:1855-63. (Pubitemid 350067646)
30. Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am 2008;34:1-15;v.